Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFACute
2022-502974-18-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rifampicin in periprosthetic joint infection (PJI) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Rate of C. spp. prosthetic joint infections management failure and Rate of adverse events linked to rifampicin. Planned start May 2023; status: authorised.
02
Drugs
rifampicin
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2022-502974-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502974-18-00.